Abbott Labs Draws Bullish Targets As Legal Overhang Fades

Abbott Laboratories’ stocks have been trading up by 10.92 percent, driven by strong medical device demand and bullish analyst upgrades.

Live Update At 14:33:11 EDT: On Thursday, July 16, 2026 Abbott Laboratories stock [NYSE: ABT] is trending up by 10.92%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ABT has been grinding higher on the chart. Over the last few weeks, Abbott Laboratories climbed from the high‑$80s to a close near $98.99, with a sharp range day from $95.29 to $101.87 showing real momentum and volatility. For short‑term traders, that wide intraday spread means opportunity, but also the need for tight risk control.

Intraday, ABT has been trading in a tight band around $99, with repeated pushes toward $100 that fade but don’t fully crack support in the high‑$98s. That screams consolidation after a strong push — classic “resting before the next move” behavior. Active traders will watch for a clean break above $101.87 as a possible continuation signal, or a drop back under the mid‑$90s as a warning that the breakout is failing.

Fundamentally, Abbott Laboratories is not a story stock with no earnings. Q1 revenue of about $11.16B came with a solid 56% gross margin and an EBIT margin near 19%. Net income of roughly $1.08B, or $0.61 diluted EPS, supports a forward profile that many analysts consider durable. A price/earnings around the mid‑20s and price‑to‑sales near 3.5 put ABT in quality MedTech territory — not cheap, but not bubble territory either. For swing traders, that mix of stable profitability and chart strength often attracts trend followers.

Why Traders Are Watching ABT Now

Right now, ABT sits at the intersection of three big storylines: fresh analyst upgrades, a cleared legal overhang, and real product catalysts in diagnostics and cardio devices.

On the Street side, Baird just initiated Abbott Laboratories at Outperform with a $121 price target, well above where ABT is trading. They are calling for 6%–8% annual sales growth and low double‑digit earnings growth, powered by new products and synergies with Exact Sciences into 2027–2028. Another note from Baird puts that $121 target above an already bullish analyst average near $115. When multiple desks lean overweight, traders pay attention — not because price targets are magic, but because they shape where big money may be looking to add.

Citi backs this up with its own sum‑of‑the‑parts view on Abbott Laboratories, landing in a $99–$104 range, again above the prior $80s–$90s trading zone. Citi’s call ties upside to easing headwinds and a new product cycle. In practice, that means they see COVID testing drag fading while Abbott’s newer devices and diagnostics step up.

On the headline risk side, the U.S. Department of Justice has finally closed its multi‑year baby‑formula investigation into Abbott’s Sturgis plant without criminal charges. The focus shifts to a civil False Claims Act settlement to recover federal nutrition‑program funds. That removes tail‑risk criminal exposure, even if reputational and financial clean‑up remains. Interestingly, ABT shares dipped around 1.3% after the non‑criminal outcome hit the tape, suggesting the market had already priced in this resolution or is more worried about civil costs and brand repair. For short‑term trading, that reaction shows how “good news” can still be a liquidity event rather than a straight relief rally.

At the same time, Abbott Laboratories is pushing its diagnostics platform forward. The ALZpath licensing deal lets ABT build an Alzheimer’s blood test using the pTau217 antibody, to be run on its widely installed Alinity ci‑series analyzers. This doesn’t flip earnings overnight, but it gives ABT a high‑value optionality play in neurodegenerative testing, where current options are expensive scans and spinal taps. Add in the expectation of some benefit from CMS’s proposed expansion of TAVR coverage for structural heart procedures, and you get a multi‑year growth runway in both diagnostics and devices.

With Q2 2026 earnings slated for 2026/07/16, all of these narratives — analyst optimism, DOJ closure, new assays, cardiovascular tailwinds — are about to be tested by real numbers and guidance. That exact timing is what momentum traders want: a crowded story heading into a defined catalyst.

Conclusion

For traders, ABT is shaping up as a classic “strong company, active catalyst” setup rather than a pure hype name. The daily chart shows Abbott Laboratories powering off the high‑$80s toward the high‑$90s, pausing under the psychological $100 level. Intraday action around $99 tells us supply and demand are almost balanced, waiting for a shove from earnings or a fresh headline. If Q2 confirms the growth path Baird and Citi are modeling, the Street’s $99–$121 band becomes a practical trading roadmap, not just an Excel exercise.

Under the hood, ABT’s 56% gross margin, solid free cash flow, and manageable leverage give the company room to keep funding innovation like the ALZpath Alzheimer’s test while supporting dividends around $2.52 per year. The DOJ’s move to close its criminal probe and focus on a civil settlement reduces tail risk, even as Abbott Laboratories spends marketing dollars — like the Similac “Love Without Measure” push — to rebuild trust in its nutrition brand.

For active traders, the key now is discipline. Watch how ABT reacts around earnings on 2026/07/16, track whether price holds above recent support in the mid‑$90s, and be ready to adapt if the story shifts. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your preparation and your rules.” As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.”. Use ABT’s catalysts, levels, and volume as data — then trade the chart, not the hype. This article is strictly for educational and research purposes and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks